title: A knockout Combo: eradicating AML Stem Cells with TKI plus SIRT1 inhibition.
abstract: SIRT1 inhibition facilitates elimination of CML stem cells by Imatinib, in part via p53 activation. In this issue of Cell Stem Cell, Li et al. (2014) demonstrate a similar role for SIRT1 inhibition in eradicating FLT3-ITD AML stem cells, potentially through a positive feedback loop with c-MYC, highlighting SIRT1 as a potential target in combination cancer therapy.
authors.affiliation: Leukaemia and Stem Cell Biology Group, Department of Haematological Medicine, Division of Cancer Studies, King's College London, London WC2R 2LS, UK.
authors.forename: Bernd B
authors.initials: BB
authors.lastname: Zeisig
authors.affiliation: Leukaemia and Stem Cell Biology Group, Department of Haematological Medicine, Division of Cancer Studies, King's College London, London WC2R 2LS, UK. Electronic address: eric.so@kcl.ac.uk.
authors.forename: Chi Wai Eric
authors.initials: CWE
authors.lastname: So
mesh_terms: D000818:Animals; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D053263:Gene Regulatory Networks; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*; D014411:Neoplastic Stem Cells / Q000473:pathology*; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics*; D056564:Sirtuin 1 / Q000378:metabolism*; D051941:fms-Like Tyrosine Kinase 3 / Q000378:metabolism*
chemical_list: D016271:Proto-Oncogene Proteins c-myc; D051941:fms-Like Tyrosine Kinase 3; D056564:Sirtuin 1